Bot Detector
Download FREE Sample Issue or Article
Subscribe Today
A subscription to IJPC provides on-line access to full-text, full-color, printable PDF copies of your subscribed issues, individual articles, and purchased archives.

Protocol of Blood Serum Eye Drops

Author(s):  Katsakoulas Ioannis, Lougovoi Claudia, Paraskevopoulou Penelope, Vougioukas Nikolaos

Issue:  May/Jun 2015 - Volume 19, Number 3
View All Articles in Issue

Page(s):  252-260

Protocol of Blood Serum Eye Drops Page 1
Protocol of Blood Serum Eye Drops Page 2
Protocol of Blood Serum Eye Drops Page 3
Protocol of Blood Serum Eye Drops Page 4
Protocol of Blood Serum Eye Drops Page 5
Protocol of Blood Serum Eye Drops Page 6
Protocol of Blood Serum Eye Drops Page 7
Protocol of Blood Serum Eye Drops Page 8
Protocol of Blood Serum Eye Drops Page 9

Download in electronic PDF format for $75

Abstract:  Keratoconjunctivitis sicca is one of the most frequent diagnoses for seeking eye care. Accumulated evidence over the past three decades has revealed a significant contribution of several molecules contained in tears at the homeostasis of the epithelium of the ocular surface. Therefore, autologous blood serum in the form of eye drops can provide substantial help in the management of keratoconjunctivitis sicca. Also making this a favorable treatment for keratoconjunctivitis sicca is the fact that this approach has become an insurance-covered benefit in some countries. This report demonstrates a formulation of blood serum eye drops with the purpose of providing an alternative to the marked absence of a universally established protocol. Exclusion criteria, equipment, preservation, dosage, duration, and guidelines for patients are described. Also included are details on the treatment of one representative embodiment. All (pre-/post-)analytical considerations and the total cost are addressed. Outcome measures such as Schirmer’ s test, break up time, and Ocular Surface Disease Index score are recorded before treatment, at 1 and 2 months, ideally as monotherapy with 100% serum q.i.d. Blood serum isolated under aseptic conditions maintained throughout is delivered as a ready-to-use formulation to the patient. Serum eye drops should be included in the modern armamentarium against keratoconjunctivitis sicca, and, hopefully, their eventual widespread application will result in coverage by most if not all insurance funds. The implementation described contributes to the hopeful establishment of a standardized protocol and provides a potentially benefit of a low-cost, applicable treatment of the ocular epithelium without side effects.

Related Keywords: Ioannis Katsakoulas, BSc, Claudia Lougovoi, PhD, Penelope Paraskevopoulou, Nikolaos Vougiouskas, blood serum eye drops, keratoconjunctivitis sicca, tears, ocular surface, autologous blood serum, drug cost, dry eye syndrome, patient exclusion criteria, Ocular Surface Disease Index, break-up time test, Rose Bengal test, Schirmer test, aseptic compounding, blood products, serologic tests


Printer-Friendly Version

Related Articles from IJPC
(Click for Abstract / Details / Purchase)
Protocol of Blood Serum Eye Drops
Katsakoulas Ioannis
, Lougovoi Claudia, Paraskevopoulou Penelope, Vougioukas Nikolaos
May/Jun 2015
Pg. 252-260

Autologous Eye Drops for the Treatment of Dry Eye and Neurotrophic Keratitis
Mixon William
, Angelle Patricea (Patsy), Chang Richard I
Nov/Dec 2009
Pg. 506-515

Long-term Stability of Epitheliotropic Factors in Frozen Serum Eye Drops
Sahyoun Jean-Yves
, Cloutier Marc, Frenette Mathieu, Robert Marie-Claude
Jul/Aug 2022
Pg. 336-341

Quality-Control Analytical Methods: Applications and Sterility of Autologous Eye Drops
Reed-Kane Dana
, Carlson Rachel A, Kupiec Thomas C, Vu Nicole
Nov/Dec 2009
Pg. 540-543

Autologous Serum Eye Drops for Severe Dry Eye Syndrome in a Patient with Chronic Graft-vs-Host Disease: A Case Report
Mixon Bill
, Mixon Jan, Isbey Edward K III, Sprinkle Shari
Sep/Oct 2014
Pg. 370-377

Stability and In Vitro Toxicity of an Infliximab Eye Drop Formulation
Robert Marie-Claude
, Spurr-Michaud Sandra, Frenette Mathieu, Young David, Gipson Ilene K, Dohlman Claes H
Sep/Oct 2014
Pg. 418-426

Measurement of Free Iodine in Different Formulations of Povidone-Iodine Eye Drops 5%
Berisa Prado Silvia
, Riestra Ayora Ana Cristina, Trelles Campa Adrián
Sep/Oct 2019
Pg. 418-421

Using Serum Hormone Analysis to Develop Hormone Replacement Therapy Regimens - Part 2
Ford Gina
, Garcia Lea
Jan/Feb 2001
Pg. 52-54

Using Serum Hormone Analysis to Develop Hormone Replacement Therapy Regimens-Part 1
Ford Gina
, Garcia Lea
Nov/Dec 2000
Pg. 421-422

Simple Preparation of Timolol 0.5% Gel from Eye Drop Solution for Superficial Infantile Hemangiomas
Choo Winnie
Jul/Aug 2017
Pg. 282-289

Tacrolimus 0.06% Ophthalmic Drops
Allen Loyd V Jr
Jul/Aug 2017
Pg. 319

Measuring Testosterone Biomarkers in Serum and Saliva: Are They Accurate?
Tan Robert S
Nov/Dec 2004
Pg. 419-423

Artificial Tears for Dry Eyes
Allen Loyd V Jr
Sep/Oct 2000
Pg. 376

Impact of Conventional and Bioidentical Hormone Replacement Therapy on Cardiovascular and Breast Health: A Review
Ruiz Andres D
, Daniels Kelly R, Barner Jamie C, Carson John J, Frei Christopher R
Jul/Aug 2011
Pg. 290-300

Basics of Compounding: 3D Printing--Pharmacy Applications, Part 2
Allen Loyd V Jr
May/Jun 2017
Pg. 215-220

Ophthalmic Toning-Lubricating Drops
Allen Loyd V Jr
Jan/Feb 2010
Pg. 70

Compounding Radiolabeled Blood Cells for Diagnostic Imaging
Hinkle George H
Nov/Dec 1999
Pg. 443-446

Canine Eye Ulceration Drops
Allen Loyd V Jr
Jul/Aug 1997
Pg. 253

Veterinary Ophthalmic Practice: Therapeutic Considerations and Common Ocular Diseases - Part 3
Davidson Gigi S
Sep/Oct 2004
Pg. 359-367

Sildenafil 0.2% Otic Drops
Holland Robert T
, Quisling Richard
May/Jun 2000
Pg. 175

Return to Top